Open AccessSGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity
Author(s) -
Liu Huiquan,
Ertay Ayse,
Peng Ping,
Li Juanjuan,
Liu Dian,
Xiong Hua,
Zou Yanmei,
Qiu Hong,
Hancock David,
Yuan Xianglin,
Huang WeiChien,
Ewing Rob M.,
Downward Julian,
Wang Yihua
Publication year - 2019
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12530
Subject(s) - triple negative breast cancer , gene knockdown , cancer research , breast cancer , in vivo , epidermal growth factor receptor , cancer , biology , tissue microarray , mapk/erk pathway , medicine , cell culture , microbiology and biotechnology , signal transduction , genetics
Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1–EGFR interaction maintains intracellular glucose levels to promote survival of cancer cells. Here, we explore the role of SGLT1 in triple‐negative breast cancer (TNBC), which is the most aggressive type of breast cancer. We performed TCGA analysis coupled to in vitro experiments in TNBC cell lines as well as in vivo xenografts established in the mammary fat pad of female nude mice. Tissue microarrays of TNBC patients with information of clinical–pathological parameters were also used to investigate the expression and function of SGLT1 in TNBC. We show that high levels of SGLT1 are associated with greater tumour size in TNBC. Knockdown of SGLT1 compromises cell growth in vitro and in vivo . We further demonstrate that SGLT1 depletion results in decreased levels of phospho‐EGFR, and as a result, the activity of downstream signalling pathways (such as AKT and ERK) is inhibited. Hence, targeting SGLT1 itself or the EGFR–SGLT1 interaction may provide novel therapeutics against TNBC.